The discovery could pave the way for new treatments, improved risk prediction, and earlier intervention for brain metastases.

A large-scale international study, led by researchers from the Gray Faculty of Medical and Health Sciences at Tel Aviv ...

The gene p53 acts as a tumor suppressor and often is called the ‘guardian of the genome.’ This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading ...

No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2007 ASCO Annual Meeting. This abstract does not include a full text component.

Over 50% of human cancers are thought to carry a mutation of the p53 gene. P53 is a master at regulating the expression of genes, influencing cellular stress response, DNA damage repair, and apoptosis ...

From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...

TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...

Figure 8: Regulation of ALDH3A1 and NECTIN4 by p53. Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz from the Sidney Kimmel ...

In a recent perspective published in the journal Cell Death and Differentiation, researchers in France, Germany, and Sweden discussed the unique mutational spectrum of the transformation-related ...

Researchers created a new kind of cancer drug that can grab a mutant protein while also carrying a second hit against the ...